JP2021178823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021178823A5 JP2021178823A5 JP2021111358A JP2021111358A JP2021178823A5 JP 2021178823 A5 JP2021178823 A5 JP 2021178823A5 JP 2021111358 A JP2021111358 A JP 2021111358A JP 2021111358 A JP2021111358 A JP 2021111358A JP 2021178823 A5 JP2021178823 A5 JP 2021178823A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- abd
- polypeptide according
- isolated
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 63
- 229920001184 polypeptide Polymers 0.000 claims 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims 56
- 150000001413 amino acids Chemical group 0.000 claims 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95744907P | 2007-08-22 | 2007-08-22 | |
| US95745307P | 2007-08-22 | 2007-08-22 | |
| US60/957,453 | 2007-08-22 | ||
| US60/957,449 | 2007-08-22 | ||
| US5298608P | 2008-05-13 | 2008-05-13 | |
| US61/052,986 | 2008-05-13 | ||
| JP2019000459A JP6910380B2 (ja) | 2007-08-22 | 2019-01-07 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000459A Division JP6910380B2 (ja) | 2007-08-22 | 2019-01-07 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021178823A JP2021178823A (ja) | 2021-11-18 |
| JP2021178823A5 true JP2021178823A5 (enExample) | 2022-05-19 |
| JP7252278B2 JP7252278B2 (ja) | 2023-04-04 |
Family
ID=40378878
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521883A Active JP6035009B2 (ja) | 2007-08-22 | 2008-08-21 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2015012223A Pending JP2015110619A (ja) | 2007-08-22 | 2015-01-26 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2016233739A Active JP6529952B2 (ja) | 2007-08-22 | 2016-12-01 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2019000459A Active JP6910380B2 (ja) | 2007-08-22 | 2019-01-07 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2021111358A Active JP7252278B2 (ja) | 2007-08-22 | 2021-07-05 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521883A Active JP6035009B2 (ja) | 2007-08-22 | 2008-08-21 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2015012223A Pending JP2015110619A (ja) | 2007-08-22 | 2015-01-26 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2016233739A Active JP6529952B2 (ja) | 2007-08-22 | 2016-12-01 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2019000459A Active JP6910380B2 (ja) | 2007-08-22 | 2019-01-07 | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (8) | US20090304719A1 (enExample) |
| EP (2) | EP2190861A4 (enExample) |
| JP (5) | JP6035009B2 (enExample) |
| AU (1) | AU2008289441A1 (enExample) |
| CA (2) | CA2697032C (enExample) |
| GB (1) | GB2455449A (enExample) |
| WO (1) | WO2009025846A2 (enExample) |
Families Citing this family (224)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2368387T5 (es) | 2000-10-09 | 2019-03-07 | Cytomx Therapeutics Inc | Anticuerpos terapéuticos y que inducen tolerancia |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| CA2696263C (en) | 2007-08-15 | 2017-06-13 | Bing Liu | Monospecific and multispecific antibodies and method of use |
| JP6035009B2 (ja) * | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| EP2398494A4 (en) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and their methods of use |
| WO2010111625A1 (en) * | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
| RS54057B1 (sr) | 2010-12-03 | 2015-10-30 | Adamed Sp. Zo.O. | Antikancerski fuzioni protein |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| JP6175372B2 (ja) * | 2011-03-04 | 2017-08-02 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
| EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
| PL394618A1 (pl) * | 2011-04-19 | 2012-10-22 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| US8822423B2 (en) | 2012-05-17 | 2014-09-02 | Janssen Biotech, Inc. | Affinity peptides toward infliximab |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| BR112014031689A2 (pt) | 2012-06-22 | 2017-07-25 | Cytomx Therapeutics Inc | anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| JP6605957B2 (ja) * | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス，インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| CN105209496A (zh) * | 2013-03-15 | 2015-12-30 | 拜尔健康护理有限责任公司 | 针对组织因子途径抑制剂的前体药物抗体 |
| EA035322B1 (ru) * | 2013-05-28 | 2020-05-28 | ДиЭсБи-ЮЭсЭй ЛЛК | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения |
| CA2913732A1 (en) | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| JP6462673B2 (ja) | 2013-07-05 | 2019-01-30 | フォーメーション バイオロジックス インコーポレイテッド | Ｅｇｆｒ抗体コンジュゲート |
| BR112016001611B1 (pt) | 2013-07-25 | 2024-01-09 | Cytomx Therapeutics, Inc | Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico |
| US20150087810A1 (en) * | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| WO2015089283A1 (en) * | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
| CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| KR20230125855A (ko) | 2014-11-21 | 2023-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73에 대항한 항체 및 그의 용도 |
| CN110256558B (zh) | 2014-12-23 | 2023-07-04 | 百时美施贵宝公司 | 针对tigit的抗体 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| AU2016215604B2 (en) | 2015-02-02 | 2020-08-13 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| CN107709363A (zh) | 2015-05-01 | 2018-02-16 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
| JP7028648B2 (ja) | 2015-05-04 | 2022-03-02 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| MY194184A (en) | 2015-05-04 | 2022-11-17 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
| HK1250037A1 (zh) | 2015-05-04 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-itga3抗体、可活化的抗-itga3抗体、及其使用方法 |
| WO2016182064A1 (ja) | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| UY36687A (es) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| US20180153884A1 (en) | 2015-05-31 | 2018-06-07 | Curegenix Corporation | Combination compositions for immunotherapy |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| DK3313874T3 (da) | 2015-06-26 | 2021-05-03 | Univ Southern California | Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering |
| EA201890162A1 (ru) | 2015-06-29 | 2018-07-31 | Бристол-Маерс Сквибб Компани | Антитела к cd40 с повышенной агонистической активностью |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| WO2017019729A1 (en) | 2015-07-27 | 2017-02-02 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
| SG10202101909RA (en) | 2015-08-07 | 2021-04-29 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
| AU2016343805A1 (en) | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| MX2018005315A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| WO2017087789A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| KR20220033522A (ko) | 2016-03-04 | 2022-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| LT3461261T (lt) | 2016-05-20 | 2025-08-25 | Harpoon Therapeutics, Inc. | Vienos grandinės kintamo fragmento cd3 surišantys baltymai |
| US11458208B2 (en) | 2016-06-06 | 2022-10-04 | Asclepiumm Taiwan Co., Ltd | Desmoglein 2 antibody fusion proteins for drug delivery |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| EP3474901B1 (en) | 2016-06-27 | 2025-08-06 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| MY200695A (en) | 2016-11-03 | 2024-01-11 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
| WO2018098354A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| CA3044729A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| TW202323287A (zh) * | 2016-11-28 | 2023-06-16 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| KR20230073346A (ko) | 2016-11-28 | 2023-05-25 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
| MA50949B1 (fr) | 2016-12-07 | 2023-12-29 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| EP3551667A4 (en) | 2016-12-09 | 2020-06-17 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
| EP3585817A4 (en) * | 2017-02-22 | 2020-12-02 | Aleta Biotherapeutics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| WO2018155611A1 (ja) | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| WO2018160671A1 (en) * | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| JP2020511130A (ja) | 2017-03-09 | 2020-04-16 | サイトメックス セラピューティクス インコーポレイテッド | Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法 |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| KR20240165484A (ko) | 2017-04-11 | 2024-11-22 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법 |
| CN108728444A (zh) | 2017-04-18 | 2018-11-02 | 长春华普生物技术股份有限公司 | 免疫调节性多核苷酸及其应用 |
| US12460208B2 (en) | 2017-04-18 | 2025-11-04 | Parr Biotechnology Co., Ltd. | Immunomodulatory polynucleotides and uses thereof |
| EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS MSLN AND METHOD OF USE |
| CN113896792B (zh) | 2017-05-12 | 2025-08-22 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| EA201992755A1 (ru) | 2017-05-19 | 2020-04-22 | Уси Байолоджикс (Шанхай) Ко. Лтд. | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) |
| WO2018219301A1 (zh) * | 2017-05-31 | 2018-12-06 | 四川大学华西医院 | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| CN111050803A (zh) * | 2017-06-20 | 2020-04-21 | 德克萨斯大学系统董事会 | 用于治疗癌症的干扰素前药 |
| CN111263758A (zh) | 2017-06-30 | 2020-06-09 | 麻省理工学院 | 支链的多官能大分子单体和相关聚合物及其用途 |
| EP3652210A1 (en) | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
| JP2020530554A (ja) | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| KR20200040819A (ko) | 2017-08-16 | 2020-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| MX2020002198A (es) | 2017-08-30 | 2020-07-20 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. |
| KR102425983B1 (ko) | 2017-10-13 | 2022-07-29 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN111278467B (zh) | 2017-10-14 | 2024-07-30 | 艾伯维公司 | 抗cd71可活化抗体药物缀合物和其使用方法 |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| CA3081539A1 (en) * | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| MX2020005160A (es) | 2017-11-28 | 2020-08-20 | Chugai Pharmaceutical Co Ltd | Molecula de union a ligando que tiene actividad de union a ligando ajustable. |
| WO2019107380A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| KR102813744B1 (ko) | 2017-12-27 | 2025-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| US20200399373A1 (en) | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| EP3762420A1 (en) | 2018-03-09 | 2021-01-13 | CytomX Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| PE20210290A1 (es) | 2018-03-21 | 2021-02-11 | Five Prime Therapeutics Inc | ANTICUERPOS DE UNION A VISTA A pH ACIDO |
| EP3773913A1 (en) | 2018-04-11 | 2021-02-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| US20210324088A1 (en) | 2018-05-02 | 2021-10-21 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| WO2019212356A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B .V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| JP7460609B2 (ja) * | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なインターロイキン－２ポリペプチド及びその使用方法 |
| EP3794044A4 (en) * | 2018-05-14 | 2022-02-16 | Harpoon Therapeutics, Inc. | DOUBLE BINDING UNIT |
| KR20210020903A (ko) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| SG11202011308VA (en) * | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable cytokine polypeptides and methods of use thereof |
| US12077577B2 (en) | 2018-05-30 | 2024-09-03 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| CN112654633B (zh) | 2018-06-22 | 2025-05-09 | 科优基因公司 | 基于细胞因子的可生物活化药物及其使用方法 |
| EP3820902A2 (en) | 2018-07-11 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
| US12195533B2 (en) | 2018-07-24 | 2025-01-14 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| AU2019314355B2 (en) * | 2018-07-31 | 2025-05-15 | Amgen Inc. | Pharmaceutical formulations of masked antibodies |
| CN113286824A (zh) | 2018-08-03 | 2021-08-20 | 中外制药株式会社 | 包含两个彼此连接的抗原结合结构域的抗原结合分子 |
| EP3837266A1 (en) | 2018-08-17 | 2021-06-23 | Massachusetts Institute of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| JP2022500400A (ja) * | 2018-09-11 | 2022-01-04 | ジョージア テック リサーチ コーポレイション | 免疫療法プロファイリングのための組成物および方法 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| TWI863932B (zh) | 2018-10-11 | 2024-12-01 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| JP2022512684A (ja) | 2018-10-11 | 2022-02-07 | インヒブルクス インコーポレイテッド | Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物 |
| TW202028245A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | Dll3單域抗體及其治療性組合物 |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| CN113260383A (zh) | 2018-11-02 | 2021-08-13 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
| JP7520003B2 (ja) | 2018-11-16 | 2024-07-22 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｎｋｇ２ａ抗体およびその使用 |
| US12049505B2 (en) | 2018-12-06 | 2024-07-30 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| KR20210142594A (ko) | 2018-12-26 | 2021-11-25 | 시티 오브 호프 | 활성화 가능한 차폐된 항-ctla4 결합 단백질 |
| JP2022523200A (ja) | 2019-02-26 | 2022-04-21 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 |
| KR20210137128A (ko) * | 2019-03-08 | 2021-11-17 | 옥스포드 제네틱스 리미티드 | 항체의 선택 방법 |
| MX2021010997A (es) | 2019-03-13 | 2021-10-01 | Merck Sharp & Dohme Llc | Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1. |
| TW202102270A (zh) | 2019-03-21 | 2021-01-16 | 美商伊繆諾金公司 | 製備細胞結合劑-藥物結合物之方法 |
| US11851487B2 (en) * | 2019-04-01 | 2023-12-26 | Rensselaer Polytechnic Institute | Methods and systems for detecting peptide aggregates |
| EP4600650A3 (en) * | 2019-04-05 | 2025-11-26 | Earli Inc. | Improved methods and compositions for synthetic biomarkers |
| KR20210153100A (ko) | 2019-04-18 | 2021-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 낮은 pH에서의 결합에 대한 증진된 특이성을 갖는 이필리무맙 변이체 |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| US20210317143A9 (en) | 2019-05-20 | 2021-10-14 | Massachusetts Institute Of Technology | Boronic ester prodrugs and uses thereof |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| US20220233709A1 (en) | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
| WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
| BR112021023735A2 (pt) | 2019-06-05 | 2022-01-04 | Chugai Pharmaceutical Co Ltd | Molécula de ligação de sítio de clivagem de anti-corpo |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| AU2020291012B2 (en) | 2019-06-12 | 2025-09-25 | AskGene Pharma, Inc. | Novel IL-15 prodrugs and methods of use thereof |
| EP3983440A1 (en) | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer |
| US20220306745A1 (en) | 2019-06-13 | 2022-09-29 | Cytomx Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer |
| WO2020256546A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| JP2022545439A (ja) * | 2019-08-21 | 2022-10-27 | アスクジーン・ファーマ・インコーポレイテッド | 新規ｉｌ－２１プロドラッグおよびその使用方法 |
| CN112480263A (zh) * | 2019-09-12 | 2021-03-12 | 普米斯生物技术(苏州)有限公司 | 一种双特异t细胞激活器活化t细胞的设计及其应用 |
| PE20220566A1 (es) | 2019-09-19 | 2022-04-13 | Bristol Myers Squibb Co | ANTICUERPOS DE UNION A VISTA A pH ACIDO |
| EP4034171A1 (en) | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| WO2021141662A1 (en) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| EP4100433A4 (en) | 2020-02-05 | 2024-03-13 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| KR20220151189A (ko) | 2020-03-09 | 2022-11-14 | 브리스톨-마이어스 스큅 컴퍼니 | 증진된 효능제 활성을 갖는 cd40에 대한 항체 |
| CA3173587A1 (en) | 2020-03-31 | 2021-10-07 | Chugai Seiyaku Kabushiki-Kaisha | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| AU2021254279A1 (en) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| JP2023520922A (ja) | 2020-04-10 | 2023-05-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構築物および関連組成物ならびに方法 |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| JP2023538098A (ja) | 2020-08-21 | 2023-09-06 | ジェンザイム・コーポレーション | Ｆｇｆｒ３抗体および使用の方法 |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| MX2023005130A (es) | 2020-11-04 | 2023-05-25 | Genentech Inc | Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3. |
| WO2022104186A1 (en) * | 2020-11-16 | 2022-05-19 | Tavotek Biotherapeutics (Hong Kong) Limited | A shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| CA3206549A1 (en) | 2021-01-29 | 2022-08-04 | Frederick G. Vogt | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| EP4305063A1 (en) * | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
| TW202304958A (zh) | 2021-03-16 | 2023-02-01 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 經遮蔽之可活化之細胞介素構築體及相關之組成物及方法 |
| EP4330282A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4337190A1 (en) | 2021-05-13 | 2024-03-20 | ALX Oncology Inc. | Combination therapies for treating cancer |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| EP4370211A1 (en) | 2021-07-14 | 2024-05-22 | Seagen Inc. | Antibody masking domains |
| EP4373862A1 (en) | 2021-07-19 | 2024-05-29 | Chugai Seiyaku Kabushiki Kaisha | Protease-mediated target specific cytokine delivery using fusion polypeptide |
| EP4405387A1 (en) | 2021-09-24 | 2024-07-31 | Seagen Inc. | Improved antibody masking domains |
| AR127343A1 (es) | 2021-10-13 | 2024-01-31 | Cytomx Therapeutics Inc | Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados |
| WO2023064937A1 (en) * | 2021-10-14 | 2023-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Programmable delivery platforms for rna structures |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| KR20240118749A (ko) | 2021-10-15 | 2024-08-05 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 폴리펩타이드 복합체 |
| IL312145A (en) | 2021-10-15 | 2024-06-01 | Amgen Inc | An activatable polypeptide complex |
| EP4442828A4 (en) | 2021-11-30 | 2025-11-12 | Daiichi Sankyo Co Ltd | Masked antibodies cleavable by protease |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| US20250170255A1 (en) | 2022-02-09 | 2025-05-29 | Daiichi Sankyo Company, Limited | Environmentally-responsive masked antibody and use thereof |
| CN119301151A (zh) | 2022-03-25 | 2025-01-10 | 西托姆克斯治疗公司 | 可激活双锚定掩蔽分子和其使用方法 |
| US20250215110A1 (en) | 2022-04-01 | 2025-07-03 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| US20250230239A1 (en) | 2022-04-01 | 2025-07-17 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023222580A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
| KR20250036813A (ko) | 2022-07-12 | 2025-03-14 | 싸이톰스 테라퓨틱스, 인크. | Epcam 면역접합체 및 이의 용도 |
| WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| EP4565690A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| US20240376170A1 (en) * | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240400614A1 (en) * | 2023-01-11 | 2024-12-05 | Bright Peak Therapeutics Ag | Cleavable peptides and methods of use thereof |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024212151A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Masked antibodies, libraries and methods of use |
| WO2025015318A2 (en) | 2023-07-13 | 2025-01-16 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| CN117534732B (zh) * | 2023-11-03 | 2024-10-22 | 湖南中晟全肽生物科技股份有限公司 | 一种抑制il-12与其受体结合的多肽及其应用 |
| US20250296991A1 (en) | 2023-12-01 | 2025-09-25 | Ablynx N.V. | Precision activated polypeptides |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5686121A (en) | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5306731A (en) * | 1985-06-14 | 1994-04-26 | Massachusetts Eye And Ear Infirmary | Method and products for treating the eye |
| US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5144012A (en) | 1988-08-08 | 1992-09-01 | Eli Lilly And Company | Cytotoxic drug conjugates |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
| US5162218A (en) | 1988-11-18 | 1992-11-10 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation |
| EP0444158B1 (en) | 1988-11-18 | 1996-01-03 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation and use |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5272253A (en) | 1991-07-01 | 1993-12-21 | Eli Lilly And Company | Cluster conjugates of drugs with antibodies |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| AU3737893A (en) | 1992-03-05 | 1993-10-05 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US6107059A (en) * | 1992-04-29 | 2000-08-22 | Affymax Technologies N.V. | Peptide library and screening method |
| EP1550729B1 (en) | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain |
| US5834247A (en) | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
| US6955900B1 (en) | 1993-02-02 | 2005-10-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof |
| US5679548A (en) | 1993-02-02 | 1997-10-21 | The Scripps Research Institute | Methods for producing polypeptide metal binding sites and compositions thereof |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US5777078A (en) | 1993-04-28 | 1998-07-07 | Worcester Foundation For Experimental Biology | Triggered pore-forming agents |
| GB9322156D0 (en) | 1993-10-27 | 1993-12-15 | Univ Newcastel Upon Tyne | Activation of molecules |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5468785A (en) | 1994-04-15 | 1995-11-21 | University Of Akron | Cobaloxime photoinitiated free radical polymerizations |
| DK0769967T3 (da) | 1994-08-19 | 2008-03-31 | Wallone Region | Konjugater der omfatter et antitumormiddel, og anvendelse heraf |
| US5877155A (en) | 1995-03-17 | 1999-03-02 | The Research Foundation Of State University Of New York | Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP4212111B2 (ja) | 1995-05-03 | 2009-01-21 | バイオエンハンスメンツ リミテッド | 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体 |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US5866341A (en) | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| NZ334595A (en) | 1996-09-09 | 2000-08-25 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage |
| US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
| US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7582298A (en) | 1997-05-19 | 1998-12-11 | Johns Hopkins University School Of Medicine, The | Tissue specific prodrug |
| US6451575B1 (en) | 1997-07-25 | 2002-09-17 | Bristol-Myers Squibb Pharma Company | Aggrecan degrading metallo proteases |
| US20030166110A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| CA2335324A1 (en) | 1998-07-17 | 2000-01-27 | Genetag Technology, Inc. | Methods for detecting and mapping genes, mutations and variant polynucleotide sequences |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| DK1121382T3 (da) | 1998-10-16 | 2006-11-13 | Biogen Idec Inc | Interferon-beta-fusionsproteiner og deres anvendelser |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US6534061B1 (en) | 1999-04-12 | 2003-03-18 | Genentech, Inc. | Tumor necrosis factor receptor homologs and nucleic acids encoding the same |
| IL129427A0 (en) * | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
| MXPA01010891A (es) | 1999-04-28 | 2002-11-07 | Univ Texas | Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf). |
| US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
| US20040146516A1 (en) * | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| ATE488529T1 (de) | 1999-07-28 | 2010-12-15 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US20050208558A1 (en) * | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
| DE19952956A1 (de) | 1999-11-03 | 2001-05-17 | Acgt Progenomics Ag | Verfahren zur Verbindung von molekularen Substanzen |
| US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| EP1278853A2 (en) * | 2000-04-11 | 2003-01-29 | Institut Pasteur | Listeria monocytogenes genome, polypeptides and uses |
| US7514067B2 (en) * | 2000-04-25 | 2009-04-07 | President And Fellows Of Harvard College | Methods for tumor diagnosis and therapy |
| US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| AU2001279630A1 (en) * | 2000-06-01 | 2001-12-11 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US6625945B2 (en) * | 2000-08-08 | 2003-09-30 | Alfred D. Commins | Balanced, multi-stud hold-down |
| US8314060B2 (en) | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| DE10045592A1 (de) * | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| US7465790B2 (en) * | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| ES2368387T5 (es) | 2000-10-09 | 2019-03-07 | Cytomx Therapeutics Inc | Anticuerpos terapéuticos y que inducen tolerancia |
| CA2432489A1 (en) | 2001-01-04 | 2002-08-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Detection of protein conformation using a split ubiquitin reporter system |
| US7141392B2 (en) | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP1355675A1 (en) | 2001-01-30 | 2003-10-29 | Universite Catholique De Louvain | Anti-tumor compounds |
| KR20040074587A (ko) | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
| WO2002066058A1 (en) | 2001-02-19 | 2002-08-29 | Merck Patent Gmbh | Modified anti-egfr antibodies with reduced immunogenicity |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| GB0118155D0 (en) * | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| DE60235761D1 (de) | 2001-08-01 | 2010-05-06 | Univ Bristol Clifton | Isoform des vegfs |
| US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030134824A1 (en) | 2001-11-12 | 2003-07-17 | Ronald Breslow | Beta-cyclodextrin dimers and phthalocyanines and uses thereof |
| ATE457741T1 (de) * | 2001-12-17 | 2010-03-15 | Univ Cardiff | Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden |
| CN101044154A (zh) * | 2002-02-14 | 2007-09-26 | 威廉·J·鲁特 | 治疗宿主中切割的嵌合分子 |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| ATE552849T1 (de) | 2002-04-12 | 2012-04-15 | Medarex Inc | Behandlungsverfahren unter verwendung von ctla-4 antikörpern |
| US20040109855A1 (en) * | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US20040116348A1 (en) * | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| JP4351430B2 (ja) | 2002-10-04 | 2009-10-28 | 財団法人癌研究会 | ナノ黒鉛構造体に結合能を有するペプチド |
| JP4959136B2 (ja) * | 2002-12-13 | 2012-06-20 | イミューノメディクス、インコーポレイテッド | 細胞内で開裂可能な結合を有する免疫接合体 |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| AU2004248138B2 (en) | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| US20050009110A1 (en) | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| AU2004261980A1 (en) * | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody CDR polypeptide sequences with restricted diversity |
| EP1668114B1 (en) | 2003-08-18 | 2009-11-04 | The Regents of the University of California | Polypeptide display libraries and methods of making and using thereof |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7985401B2 (en) * | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US20050255042A1 (en) | 2003-11-24 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer, University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| WO2005067980A2 (en) | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| EP1579873A1 (en) | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| JP4246121B2 (ja) | 2004-07-29 | 2009-04-02 | 株式会社リコー | 静電潜像現像用カラーキャリア及び現像剤 |
| EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | A BLOODED ELEMENT WHICH IS SELECTLY Degraded in TUMOR TISSUE |
| JP5137814B2 (ja) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| DE102005036542A1 (de) | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF |
| US20090130776A1 (en) | 2005-09-01 | 2009-05-21 | Canon Kabushiki Kaisha | Binding protein molecule |
| EP1770099A1 (en) | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| EP1976861A2 (en) | 2005-11-29 | 2008-10-08 | The Scripps Research Institute | Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain |
| TW200804425A (en) | 2005-12-06 | 2008-01-16 | Domantis Ltd | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
| GB0604187D0 (en) | 2006-03-02 | 2006-04-12 | Fusion Antibodies Ltd | Peptide and uses thereof |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| EP1998684A4 (en) | 2006-03-10 | 2014-09-17 | Massachusetts Inst Technology | CONJUGATES AND NANOSYSTEMS WITH TRIGGERED SELF ASSEMBLY |
| SG170750A1 (en) | 2006-03-17 | 2011-05-30 | Biogen Idec Inc | Stabilized polypeptide compositions |
| WO2008052322A1 (en) | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| US20080317677A1 (en) | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
| KR20100063048A (ko) | 2007-07-31 | 2010-06-10 | 더 존스 홉킨스 유니버시티 | 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체 |
| US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| JP6035009B2 (ja) * | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| EP2200634B1 (en) | 2007-09-21 | 2015-02-11 | The Regents of The University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| US20110178279A1 (en) | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| WO2010077643A1 (en) | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Masking ligands for reversible inhibition of multivalent compounds |
| EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| EP2398494A4 (en) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and their methods of use |
| US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
-
2008
- 2008-08-21 JP JP2010521883A patent/JP6035009B2/ja active Active
- 2008-08-21 US US12/196,269 patent/US20090304719A1/en not_active Abandoned
- 2008-08-21 AU AU2008289441A patent/AU2008289441A1/en not_active Abandoned
- 2008-08-21 EP EP08795508A patent/EP2190861A4/en not_active Withdrawn
- 2008-08-21 EP EP18200815.1A patent/EP3492488A1/en active Pending
- 2008-08-21 WO PCT/US2008/009974 patent/WO2009025846A2/en not_active Ceased
- 2008-08-21 CA CA2697032A patent/CA2697032C/en active Active
- 2008-08-21 CA CA3128656A patent/CA3128656A1/en active Pending
-
2009
- 2009-02-16 GB GB0902572A patent/GB2455449A/en not_active Withdrawn
-
2012
- 2012-03-02 US US13/411,409 patent/US8518404B2/en active Active
- 2012-03-02 US US13/411,416 patent/US8541203B2/en active Active
- 2012-03-06 US US13/413,447 patent/US8529898B2/en active Active
-
2013
- 2013-07-24 US US13/950,174 patent/US9169321B2/en active Active
-
2015
- 2015-01-26 JP JP2015012223A patent/JP2015110619A/ja active Pending
- 2015-09-14 US US14/853,840 patent/US10077300B2/en active Active
-
2016
- 2016-12-01 JP JP2016233739A patent/JP6529952B2/ja active Active
-
2018
- 2018-08-13 US US16/102,531 patent/US11028162B2/en active Active
-
2019
- 2019-01-07 JP JP2019000459A patent/JP6910380B2/ja active Active
-
2021
- 2021-04-30 US US17/245,713 patent/US12209120B2/en active Active
- 2021-07-05 JP JP2021111358A patent/JP7252278B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021178823A5 (enExample) | ||
| JP2022046569A5 (enExample) | ||
| JP2012514982A5 (enExample) | ||
| JP2022065174A5 (enExample) | ||
| CN102272159B (zh) | 结合SPARC的ScFv | |
| JP2017523176A5 (enExample) | ||
| JPWO2020118109A5 (enExample) | ||
| Azemar et al. | Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2 | |
| CN101243191B (zh) | 用于检测甲基化dna的手段和方法 | |
| JP2015516813A5 (enExample) | ||
| RU2011133819A (ru) | Композиции модифицированных антител, способы их получения и применения | |
| JP2016521707A5 (enExample) | ||
| CN105744944B (zh) | 免疫系统调节器 | |
| KR101370797B1 (ko) | 알부민 결합 펩티드-매개 질병 표적화 | |
| JP2010536370A5 (enExample) | ||
| JP2018504925A5 (enExample) | ||
| WO2003034903B1 (en) | Psma antibodies and protein multimers | |
| WO2008122039A2 (en) | Selenocysteine mediated hybrid antibody molecules | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| JP2010534061A (ja) | 組換えコレラ菌外毒素 | |
| US5879898A (en) | Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors | |
| CN116655799A (zh) | 包括可切割接头的il-2细胞因子前药 | |
| US7563765B2 (en) | Histidine-rich glycoprotein | |
| KR20230077720A (ko) | Mucin-1에 특이적인 항체 및 이의 사용 방법 | |
| EP1539817B1 (en) | Immunoassays for specific determination of scca isoforms |